Cure My Disease

Don't miss your cure!

 Log in / Sign up

Steroid injection during fibroid procedure may ease Post-Op pain

NCT ID NCT04655144

Symptom relief Sponsor: University of Miami Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving an anti-inflammatory steroid directly into the uterine arteries during a non-surgical fibroid treatment can lessen pain, nausea, vomiting, and tiredness afterward. Forty-two women with symptomatic fibroids took part. The goal was to see if this simple addition could make recovery more comfortable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

42 people

The number who actually took part.

Started

Jan 2021

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women who meet criteria to undergo uterine fibroid embolization for symptomatic fibroids. Exclusion Criteria: * Currently pregnant or actively attempting to conceive * Those deemed mentally impaired to make their own medical decisions * Previous documented allergy to dexamethasone * Those currently taking daily steroids for any reason * Those with diabetes or deemed to be pre-diabetic * Those with contraindications for angiography * Prisoners

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Leiomyoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leiomyoma uterine corpus leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leiomyoma

Contacts and locations

Locations

  • Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.